Victory Capital Management
ADPT icon

Victory Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Victory Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.43M Sell
390,855
-96,851
-20% -$1.54M ﹤0.01% 1290
2025
Q4 		$7.92M Sell
487,706
-758,867
-61% -$12.4M ﹤0.01% 1133
2025
Q3 		$18.6M Sell
1,246,573
-456,627
-27% -$5.56M 0.01% 900
2025
Q2 		$19.8M Sell
1,703,200
-61,027
-3% -$554K 0.01% 878
2025
Q1 		$13.1M Buy
1,764,227
+1,746,571
+9,892% +$13.4M 0.01% 953
2024
Q4 		$106K Sell
17,656
-409
-2% -$2.25K ﹤0.01% 2332
2024
Q3 		$92.5K Sell
18,065
-308
-2% -$1.34K ﹤0.01% 2333
2024
Q2 		$66.5K Sell
18,373
-299
-2% -$949 ﹤0.01% 2340
2024
Q1 		$59.9K Sell
18,672
-415
-2% -$1.61K ﹤0.01% 2362
2023
Q4 		$93.5K Buy
19,087
+3,509
+23% +$16K ﹤0.01% 2351
2023
Q3 		$84.9K Buy
15,578
+209
+1% +$1.38K ﹤0.01% 2323
2023
Q2 		$103K Sell
15,369
-358
-2% -$2.66K ﹤0.01% 2302
2023
Q1 		$139K Sell
15,727
-164
-1% -$1.45K ﹤0.01% 2313
2022
Q4 		$121K Sell
15,891
-6
-0% -$47 ﹤0.01% 2336
2022
Q3 		$113K Sell
15,897
-1,087
-6% -$10.2K ﹤0.01% 2454
2022
Q2 		$137K Buy
16,984
+3,166
+23% +$27.8K ﹤0.01% 2416
2022
Q1 		$114K Buy
13,818
+267
+2% +$4.2K ﹤0.01% 2497
2021
Q4 		$380K Sell
13,551
-15,065
-53% -$462K ﹤0.01% 2297
2021
Q3 		$973K Sell
28,616
-436
-2% -$15.8K ﹤0.01% 1875
2021
Q2 		$1.19M Buy
29,052
+1,448
+5% +$56.3K ﹤0.01% 1832
2021
Q1 		$1.11M Sell
27,604
-28,017
-50% -$1.52M ﹤0.01% 1871
2020
Q4 		$3.29M Sell
55,621
-5,010
-8% -$258K ﹤0.01% 1359
2020
Q3 		$2.95M Sell
60,631
-8,048
-12% -$338K ﹤0.01% 1323
2020
Q2 		$3.32M Sell
68,679
-268,899
-80% -$9.8M ﹤0.01% 1274
2020
Q1 		$9.38M Buy
337,578
+261,172
+342% +$7.28M 0.01% 1103
2019
Q4 		$2.29M Sell
76,406
-11,604
-13% -$333K ﹤0.01% 1454
2019
Q3 		$2.72M Buy
88,010
+27,010
+44% +$1.1M ﹤0.01% 1348
2019
Q2 		$2.95M Buy
+61,000
New +$2.7M 0.01% 1043

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Victory Capital Management's ADPT Position: Q1 2026 in Review

Victory Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 20% in Q1 2026, selling an estimated $1.54M and leaving 390,855 shares worth $5.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Victory Capital Management first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $19.8M in Q2 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Victory Capital Management held 390,855 shares of Adaptive Biotechnologies worth $5.43M as of Q1 2026.
  • Victory Capital Management sold 96,851 Adaptive Biotechnologies shares in Q1 2026, an estimated $1.54M.
  • Adaptive Biotechnologies made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1290 holding.
  • Victory Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Adaptive Biotechnologies position peaked at $19.8M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.